CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference

MONMOUTH JUNCTION, N.J., March 13, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it will exhibit its European Union approved CytoSorb® cytokine reduction technology at the 33^rd International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium from March 19-22, 2013.  In addition, Dr. Dirk Schadler, from the University Hospital, Universitatsklinikum Schleswig-Holstein, at Kiel University, Kiel, Germany, was selected to present a poster (#P062) at the conference entitled, "A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients." Finally, CytoSorbents will also host an evening that will bring together current and potential customers to talk about critical care medicine and to share real world experiences using CytoSorb®.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "We are pleased at the growing recognition and usage of CytoSorb® by leading experts in the field of critical care medicine in many different applications. We have already seen exciting cases in such areas as sepsis, burn injury, trauma, lung injury, cardiac surgery, liver failure, pancreatitis, influenza, and other indications.  Users have confirmed the simplicity and ease of use of the CytoSorb® therapy.  As we expand our commercialization efforts, we look forward to beginning a number of investigator-initiated studies this year in many different areas that may help drive future adoption and awareness for our technologies."

About ISICEM
The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses commonly seen in the intensive care unit such as sepsis and infection, influenza, severe lung injury, trauma, burn injury, and pancreatitis. Its purification technology is based upon biocompatible, highly porous polymer beads that can efficiently remove toxic substances from blood and other bodily fluids. The Company's flagship product CytoSorb^®, a first-in-class extracorporeal cytokine filter compatible with standard hemodialysis machines, has achieved European Union CE Mark regulatory approval and is now being commercialized in Europe. The goal of the CytoSorb^® cytokine filter is to prevent or treat multiple organ failure, the leading cause of death in the intensive care unit, by reducing the excessive production of cytokines, or "cytokine storm", that could otherwise lead to deadly inflammation, organ injury, and death.  Organ failure represents one of the most serious unmet medical needs in modern medicine, claiming millions of lives around the world, at a cost of tens of billions of dollars, each year.  By actively addressing one of the most important underlying causes of organ failure, CytoSorb^® represents a potentially revolutionary advance in the treatment of critical illnesses. 

CytoSorbents has been awarded $5 million in contracts from both DARPA and the US Army, and continues to invest significantly in its research and development pipeline.  One of its most advanced products under development is HemoDefend, a blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and improve the safety of "old" blood by removing many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions. 

CytoSorb^® and HemoDefend are just two of a number of different polymers the Company has developed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 31, 2012, which is available at http://www.sec.gov.

Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
[email protected]

Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
[email protected]

Valter Pinto
(914) 669-0222 x201
[email protected]

SOURCE CytoSorbents Corporation